NORTHWEST BIOTHERAPEUTICS INC (NWBO) Form 10-Q — Aug 14, 2026
Northwest Biotherapeutics reported a net loss of $12.3 million for the six months ended June 30, 2026, narrowing sharply from $34.7 million a year earlier, with a Q2 net loss of $9.2 million versus $15.4 million. Six-month revenue rose to $1.3 million from $0.5 million while R&D and G&A costs declined. The company disclosed substantial doubt about its ability to continue as a going concern, holding just $595 thousand in cash at June 30, 2026 against $73.4 million of current liabilities and $110.7 million of total liabilities.
Key figures
- Revenue
- $1.301M for six months ended June 30, 2026 (vs $0.506M prior year); $0.807M in Q2 2026 (vs $0.131M)
- Net Income
- -$12.29M for six months ended June 30, 2026 (vs -$34.72M prior year); -$9.22M in Q2 2026 (vs -$15.38M)
- Total Debt
- $51.97M carrying value ($65.55M face value) as of June 30, 2026
- Cash Position
- 595000
- Shares Outstanding
- 1705637993
- Q2 Revenue
- 807000
- Yorkville Note
- 4900000
- H1 Debt Converted
- $9.8M convertible notes converted into 48.9M shares at ~$0.20 weighted average price
- Total Liabilities
- 110717000
- Yorkville Warrant
- 2000000
- Current Liabilities
- 73352000
- Ga Expense Six Months
- 13243000
- Rd Expense Six Months
- 10563000
- Yorkville Warrant Strike
- 0.205
- Yorkville Standby Equity Facility
- 50000000
- Debt Extinguishment Loss Six Months
- 6936000
AI analysis
Red flags8 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.